The Veri-te™ resveratrol team at Evolva are delighted to announce that we have added a new technical brochure on resveratrol and blood glucose to our portfolio.
In clinical studies resveratrol has been found to:
- significantly lower fasting glucose, insulin and insulin resistance
in subjects with Type II Diabetes
- significantly lower systolic, arterial and pulse blood pressure in diabetic
- also benefit the general population
- support some diabetes-derived conditions such as diabetic retinopathy, neuropathy and nephropathy and foot ulcers